1st Annual European Symposium on Lung Cancers

7-8 July 2017 Barcelona, Spain

Xcovery will be in attendance at the 1st Annual European Symposium on Lung Cancers in Barcelona, Spain July 7th-8th, 2017.

ASCO 2017 Annual Meeting

 

Xcovery presented the eXalt3 trial design at ASCO 2017.

18th Annual International Lung Cancer Congress

 

Xcovery will be in attendance at the 18th Annual International Lung Cancer Congress in Huntington Beach, California July 27th- July 29th, 2017.

eXist:

How you want to

PATIENT STORY TITLE

Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te feugait nulla facilisi.

Lorem ipsum dolor sit amet, cons ectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.

eXplore:

Your Opportunities

 

eXalt3 STUDY NOW RECRUITING
FOR ALK+ LUNG CANCER

If you have been recently diagnosed with lung cancer and your doctor told you that your disease is called “ALK+ lung cancer”, you might be eligible for taking part in our clinical study eXalt3.

 

eXalt2 STUDY NOW RECRUITING
FOR ALK+ LUNG CANCER

If you have been diagnosed with ALK+ lung cancer and you have previously received a drug called either crizotinib or alectinib to treat your disease, you might be eligible for taking part in our clinical study eXalt2.

eXamine:

Options for Your Patients

eXalt3 and eXalt2 studies for ALK+ NSCLC

We are now recruiting treatment-naïve  and previously treated (crizotinib or alectinib) ALK+ NSCLC patients for our clinical studies eXalt3 and eXalt2, respectively.

eXalt3 and eXalt2 studies for ALK+ NSCLC 

We are now recruiting treatment-naïve  and previously treated (crizotinib or alectinib) ALK+ NSCLC patients for our clinical studies eXalt3 and eXalt2, respectively.